# **GMS5222 Introduction to Health Economic Modelling**

Meeting time: Weekly from 6.00-9.00pm SGT

Meeting Location: Zoom

Instructors: Junxing Chay PhD, Eric Finkelstein PhD

# **Synopsis of Course Content**

This course aims to equip students with skills required to perform their own cost-effectiveness analyses of health technologies and to critically assess the quality of evaluations conducted by others. This course begins with an introduction to key concepts in economic evaluation and decision-analytic modelling. We then transition to building decision-analytic models. We focus on two models commonly used in cost-effectiveness analyses in healthcare: namely decision trees and Markov models. The course includes hands-on-training on how to build these models in Microsoft Excel using real-world examples, so students understand how to implement these methods from first principles.

# **Prerequisites**

None.

# **Textbooks**

Weekly readings (textbook chapters and published articles) are provided under each lecture.

## **Software**

Microsoft Excel

## **Performance Assessment**

Performance will be assessed on i) short in-class quizzes at the beginning of each lecture; ii) assignments; iii) a group presentation; and iv) a final assessment. Assignments 1 and 2 can be completed individually or in groups of up to 3 students.

# Grade Breakdown

Component		Weightage (%)	Assessment Due Date
1.	Weekly in-class quizzes	30%	N/A
		(Excluding the	
		two lowest scores)	
2.	Assignment 1	10%	Week 8
3.	Assignment 2	10%	Week 11
4.	Group Presentation	20%	Week 12
5.	Final Assessment	30%	Week 13

## **Course Outline**

Week	Lecture	Lead Instructor
1	Five Steps to develop a value proposition for health innovations: Examples from Obesity	Eric Finkelstein
2	Quantifying Economic Burden	Eric Finkelstein
3	Valuing Health Gains	Eric Finkelstein
4	Introduction to Cost-Effectiveness Analysis	Eric Finkelstein
5	Decision Trees and Applications	Junxing Chay
6	Decision Tree Modelling Exercise*	Junxing Chay
7	Reporting and Interpreting Uncertainty	Junxing Chay
8	Markov Models and Applications	Junxing Chay
9	Markov Modelling Exercise I*	Junxing Chay
10	Markov Modelling Exercise II*	Junxing Chay
11	Estimating Transition Probabilities for Decision Modelling	Junxing Chay
12	Appraisal of CEA Articles (Group Presentation)	All
13	Final Assessment	N/A

<sup>\*</sup>Flipped class

# Week 1: Five Steps to develop a value proposition for health innovations: Examples from Obesity

# **Class Outline:**

Five Steps to Develop a Value Proposition for Health Innovations

- Quantifying burden
- Showing intervention effectiveness
- Showing cost-effectiveness
- Quantifying market/budget impact
- Incorporating non-economic arguments

# **Reading List for Week 1:**

• Finkelstein, E. A., Krishnan, A., & Doble, B. (2020). Beyond cost-effectiveness: A five-step framework for appraising the value of health technologies in Asia-Pacific. *The International Journal of Health Planning and Management*, 35(1), 397-408.

# **Week 2: Quantifying Economic Burden**

# **Class Outline:**

- Review exercise: ROI for bariatric surgery
- Common approaches for quantifying economic burden.
  - o Econometric approach
  - o Epidemiological (PAF) approach
- Key considerations in economic evaluation

• In-class exercises

# **Reading List for Week 2:**

- Gray et al., Applied methods of cost-effectiveness analysis in healthcare. Ch 6.
- Drummond et al., *Methods for the Economic Evaluation of Health Care Programmes*, 4<sup>th</sup> Ed. Oxford University Press. Ch 7.

# Week 3: Valuing Intervention Costs and Health Gains

## **Class Outline:**

# Intervention costing

- I. Costing strategies and perspectives.
- II. Activity Based Costing (ABC) method.
- III. Costing considerations.

# Determine intervention effectiveness.

- I. Introduction to quality-adjusted life years (QALYs) and QoL weights.
- II. Direct and indirect valuation methods of determining QoL weights.
- III. Mapping between non-preference-based and preference-based measures
- IV. Using discrete choice experiments to elicit preferences.
- V. Limitations of QALYs.
- VI. In-class exercises.

# **Reading List for Week 3:**

- Gray et al., Applied methods. Ch 5.
- Drummond et al., Methods. Ch 5, Ch. 6.

# Week 4: Introduction to Cost-Effectiveness and Budget Impact Analyses

## **Class Outline:**

- I. Conducting CEA with multiple interventions
- II. Thinking about the CEA threshold
- III. Step 4: Budget Impact/Market Analysis
- IV. In-class exercises

# **Reading List for Week 4:**

- Gray et al., *Applied methods*. Ch 2.
- Drummond et al., Methods. Ch 4.

# **Week 5. Decision Trees and Applications**

## **Class Outline:**

- I. Elements and selection of decision-analytic models for economic evaluation
- II. Elements and mechanics of decision trees
- III. Advantages and limitations of using decision trees.
- IV. Examples and appraisal of studies using decision trees.

# **Reading List:**

- Gray et al., *Applied methods*. Ch 8.
- Drummond et al., *Methods*. Ch 9.

- [Optional] Barton, P., Bryan, S., & Robinson, S. (2004). Modelling in the economic evaluation of health care: selecting the appropriate approach. Journal of health services research & policy, 9(2), 110-118.
- [Optional] Dong, D., Sung, C., & Finkelstein, E. A. (2012). Cost-effectiveness of HLA-B\* 1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore. Neurology, 79(12), 1259-1267.

# **Week 6: Decision Tree Modelling Exercise**

#### **Class Outline:**

This class will be conducted as a flipped classroom. Students should watch and practice along with the pre-recorded tutorial before class. During class, students will form groups of up to 4 to complete decision tree modelling exercises and present their models to peers for feedback.

# **Reading List:**

• Pre-recorded tutorial on building decision trees in Excel

## **Assignment**:

• Assignment 1 will require students to build, analyse and interpret a decision tree model using Excel. Please submit your assignment before the start of class in Week 8.

# **Week 7: Reporting and Interpreting Uncertainty**

# **Class Outline:**

- I. Sources of model variability: uncertainty, heterogeneity, and sampling variability
- II. Deterministic sensitivity analysis (one-way, two-way)
- III. Probabilistic sensitivity analysis
- IV. Examples and appraisal of sensitivity analysis from studies
- V. [Time permitting] Value of information analysis

# **Reading List:**

- Gray et al., *Applied methods*. Ch 10.
- Drummond et al., *Methods*. Ch 11.
- Briggs et al. (2012). Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modelling Good Research Practices Task Force-6. Value in Health, 15(6), 835-842.
- [*Optional*] Dong, D., Sung, C., & Finkelstein, E. A. (2012). Cost-effectiveness of HLA-B\* 1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore. *Neurology*, 79(12), 1259-1267.
- [*Optional*] Lin, F. J., Shyu, K. G., Hsieh, I. C., Sheu, W. H. H., Tu, S. T., Yeh, S. J., ... & Yeh, H. I. (2020). Cost-effectiveness of statin therapy for secondary prevention among patients with coronary artery disease and baseline LDL-C 70–100 mg/dL in Taiwan. Journal of the Formosan Medical Association, 119(5), 907-916.
- [*Optional*] Pandya, A., Gupta, A., Kamel, H., Navi, B. B., Sanelli, P. C., & Schackman, B. R. (2015). Carotid artery stenosis: cost-effectiveness of assessment of cerebrovascular reserve to guide treatment of asymptomatic patients. *Radiology*, 274(2), 455-463.
- [Optional] Ong, J. C. M., Than, H., Tripathi, S., Gkitzia, C., & Wang, X. (2023). A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged> 12 years in Singapore. Cost Effectiveness and Resource Allocation, 21(1), 34.

# **Week 8: Markov Models and Applications**

# **Class Outline:**

- I. Elements and mechanics of Markov models
- II. Advantages and limitations of using Markov models
- III. Examples and appraisal of studies using Markov models

# **Reading List:**

- Gray et al., Applied methods. Ch 9.
- Drummond et al., Methods. Ch 9.
- [Optional] Doble, B., Finkelstein, E. A., Tian, Y., Saxena, N., Patil, S., Wong, T. Y., & Cheung, C. M. G. (2020). Cost-effectiveness of intravitreal ranibizumab with verteporfin photodynamic therapy compared with ranibizumab monotherapy for patients with polypoidal choroidal vasculopathy. JAMA ophthalmology, 138(3), 251-259.
- [Optional] Chay, J., Fenner, B. J., Finkelstein, E. A., Teo, K. Y., & Cheung, C. M. G. (2022). Real-world cost-effectiveness of anti-VEGF monotherapy and combination therapy for the treatment of polypoidal choroidal vasculopathy. *Eye*, 36(12), 2265-2270.

# Week 9: Markov Modelling Exercise I

#### **Class Outline:**

This class will be conducted as a flipped classroom. Students should watch and practice along with the pre-recorded tutorial before class. During class, students will form groups of up to 4 to complete Markov modelling exercises and present their models to peers for feedback.

## **Reading List:**

Pre-recorded tutorial on building Markov models in Excel

# **Assignment**:

• Assignment 2 will require students to build, analyse and interpret a Markov model using Excel. Please submit your assignment before the start of class in Week 11.

# Week 10: Markov Modelling Exercise II

## **Class Outline:**

This class will continue the Markov modelling exercise from the previous week. During class, students will form groups of up to 4 to complete Markov modelling exercises and present their models to peers for feedback.

# **Week 11: Estimating Transition Probabilities for Decision Modelling**

# **Class Outline:**

- I. Introduction to survival analysis
- II. Adjusting transition probabilities using published data
- III. Estimating transition probabilities from observational data

# **Reading List:**

- Gray et al., Applied methods of cost-effectiveness analysis in healthcare. Chapter 3 and 4.
- Gidwani, R., & Russell, L. B. (2020). Estimating transition probabilities from published evidence: a tutorial for decision modelers. *Pharmacoeconomics*, 38(11), 1153-1164.

• [Optional] Aguiar, P. N., Haaland, B., Park, W., San Tan, P., Del Giglio, A., & de Lima Lopes, G. (2018). Cost-effectiveness of osimertinib in the first-line treatment of patients with EGFR-mutated advanced non–small cell lung cancer. JAMA oncology, 4(8), 1080-1084.

# **Assignment**:

• Students will work in groups to critique an assigned CEA article and present their findings to the class. Presentations will take place in week 12. More information will be provided.

# **Week 12: Appraisal of CEA Articles (Group Presentation)**

# **Class Outline:**

In this class, students will present their group's appraisal of an assigned CEA article. More information will be provided.

# Week 13: Final Assessment

# **Class Outline:**

Students will work individually to conceptualize and implement a decision-analytic model in Excel, and use it to conduct cost-effectiveness analysis. More information will be provided.